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Abstract
Background: In most resource limited settings, new tuberculosis (TB) patients are usually treated as outpatients. We sought
to investigate the reasons for hospitalisation and the predictors of poor treatment outcomes and mortality in a cohort of
hospitalized new TB patients in Kampala, Uganda
Methods and findings: Ninety-six new TB patients hospitalised between 2003 and 2006 were enrolled and followed for two
years. Thirty two were HIV-uninfected and 64 were HIV-infected. Among the HIV-uninfected, the commonest reasons for
hospitalization were low Karnofsky score (47%) and need for diagnostic evaluation (25%). HIV-infected patients were
commonly hospitalized due to low Karnofsky score (72%), concurrent illness (16%) and diagnostic evaluation (14%). Eleven
HIV uninfected patients died (mortality rate 19.7 per 100 person-years) while 41 deaths occurred among the HIV-infected
patients (mortality rate 46.9 per 100 person years). In all patients an unsuccessful treatment outcome (treatment failure,
death during the treatment period or an unknown outcome) was associated with duration of TB symptoms, with the odds
of an unsuccessful outcome decreasing with increasing duration. Among HIV-infected patients, an unsuccessful treatment
outcome was also associated with male sex (P = 0.004) and age (P = 0.034). Low Karnofsky score (aHR= 8.93, 95% CI 1.88 –
42.40, P = 0.001) was the only factor significantly associated with mortality among the HIV-uninfected. Mortality among the
HIV-infected was associated with the composite variable of CD4 and ART use, with patients with baseline CD4 below
200 cells/mL who were not on ART at a greater risk of death than those who were on ART, and low Karnofsky score
(aHR= 2.02, 95% CI 1.02 – 4.01, P = 0.045).
Conclusion: Poor health status is a common cause of hospitalisation for new TB patients. Mortality in this study was very
high and associated with advanced HIV Disease and no use of ART.
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Introduction
Improving tuberculosis (TB) treatment outcomes, including
reducing mortality is part of the Millennium Development Goals.
[1] Although TB-associated mortality was estimated to have
decreased by 41% in 2011 from that reported in 1990, substantial
morbidity and mortality is still recorded worldwide especially in
low and middle income countries.[2] The number of TB deaths
among HIV-uninfected people in 2011 was estimated as 990 000
(uncertainty interval of 0.84 million–1.1 million) [2]. An additional
430,000 deaths (uncertainty interval of 0.40 million–0.46 million)
occurred among TB patients infected with HIV. [2]
Generally, TB is associated with higher morbidity and mortality
among those infected with HIV. [3–5] Previous studies have
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attributed this to HIV/AIDS disease progression, [6] delayed
diagnosis of TB and/or HIV, [7] drug-resistant TB (DR-TB), [5,8]
and a lack of immediate access to effective treatment. [9] A higher
case fatality rate has also been associated with advanced age,
extensive disease on chest X-ray and other co morbidities. [10–12]
Several recommendations to improve outcomes of patients with
TB have been implemented such as early diagnosis and directly
observed therapy (DOT), [13] concurrent cotrimoxazole therapy
[14,15] and antiretroviral therapy (ART) in HIV infected patients
have been implemented [16,17]. However, whereas ART has
been shown to be beneficial in TB/HIV infected patients, only
about 30% of these patients access ART in most resource limited
settings even after presentation to health care facilities with
advanced HIV disease. [18]
The continued occurrence of high TB mortality rates despite
effective treatment requires studies to investigate the determinants
of mortality in different subsets of TB patients, particularly those at
high risk of death. One such subset of patients is hospitalised new
TB patients. The World Health Organization (WHO) defines new
TB patients as individuals with no prior history of TB treatment or
who have been treated for TB for less than one month. [19–21]
Previous studies have documented excess mortality among
hospitalized TB patients [22–24]. We have previously reported
poor outcomes in a cohort of retreatment TB cases in which most
of the mortality was attributable to drug-resistance [8]. In this
study, we investigate the reasons for hospitalisation, poor
treatment outcomes (treatment failure, relapse and mortality)
and their predictors in a cohort of hospitalized new TB patients at
a referral hospital in Kampala, Uganda.
Methods
Ethics
The study protocol was approved by the AIDS research sub-
committee of the Uganda National Council of Science and
Technology with additional clearance from the Institutional
Review Boards of the University of Medicine and Dentistry of
New Jersey and the London School of Hygiene & Tropical
Medicine.
Setting
The study was conducted at the 85-bed inpatient TB ward of
the National TB and Leprosy Program (NTLP) Chemotherapy
Centre at Mulago National Referral Hospital in Kampala,
Uganda. The NTLP Centre serves both as a local treatment
clinic (largest in Kampala) and as the national referral centre
(approximately one third of attendees are referral cases). This unit
has a dedicated ward for admission of TB patients for retreatment
(daily injection of streptomycin), for management of complications
of TB and for new TB patients with severe disease who need
hospitalization.
Patients
All new TB patients hospitalized from July 2003 to January
2007 were eligible for inclusion in the study, provided they were 18
years or older and gave written informed consent. Eligible subjects
were included in the study if they provided sputum specimens that
were positive for acid-fast bacilli (AFB) on smear microscopy and
TB was confirmed subsequently by growth of M. tuberculosis in
culture. A standard questionnaire was administered to patients
regarding risk factors for TB disease, and a presence or absence of
symptoms and their duration, clinical examination was performed
on all patients at enrolment and a postero-anterior chest
radiograph was graded by an experienced clinician for extent of
disease on a four-category ordinal scale. HIV testing was
performed at study enrolment after counselling and informed
consent. Patients that were found to be HIV seropositive had CD4
counts performed.
Treatment and Follow up
All patients were offered TB treatment based on the standard 8-
month WHO-recommended Category I treatment regimen
comprising 2 months of rifampicin (R), isoniazid (H), pyrazin-
amide (Z), ethambutol (E), followed by 6 months of H and E (2
RHZPE/6 HE) [21]. In accordance with existing national
guidelines, HIV infected patients received cotrimoxazole prophy-
laxis and those with a CD4+ cell count less than 200 cells/ml were
referred for ART though access to ART was limited in Kampala
before 2005. Patients received daily DOT while admitted to the
hospital and were discharged from the hospital at the discretion of
the attending physician when judged to be sufficiently recovered to
continue treatment on an ambulatory basis. After hospital
discharge, subjects were seen monthly during their 8-month TB
treatment course, at month 9, and quarterly thereafter for the
duration of the study. Patients who did not keep their scheduled
visits were traced at their homes. During follow-up visits, home
health visitors assessed treatment adherence through treatment
card review, monthly pill counts, and patient self-reporting.
Adherence was categorized into a five-level ordinal scale (fully
adherent, missed less than 20% of doses, missed about one half of
the doses, missed most doses, and not adherent at all). The worst
assessment at any visit was taken as the summary measure of
adherence for each subject. Because of small numbers of patients
in some categories, patients were classified in the analyses as either
‘‘mostly adherent’’ (consisting of the first two categories) or
‘‘missed half or more’’ (consisting of the remaining three
categories).
Laboratory Methods
Sputum specimens were processed with the standard digestion
and decontamination method using NALC/Na citrate/NaOH.
Centrifuged pellets were re-suspended in a phosphate buffer
solution and used to prepare smears and cultures on 7H10
Middlebrook agar and liquid media. Sputum smear microscopy
was performed using auramine O fluorescent stain and reported
according to the United States Centers for Disease Control and
Prevention (CDC) microscopy grading scheme (negative or 1+ to
4+). [19] Sputum sediments were cultured in either BACTECTM
460 or BACTEC MGITTM 960 (Becton Dickinson Diagnostic
Instrument Systems, Sparks, USA) according to the manufactur-
er’s recommendations [25,26]. Confirmation of M. tuberculosis
complex was determined by either the BACTEC NAP test (BD,
Sparks, USA) or PCR for IS6110 as previously described. [27]
The number of days from inoculation of 12B media until positive
(growth index .30) BACTEC culture was determined for baseline
specimens. Initial M. tuberculosis isolates obtained from each patient
at the time of recruitment were subjected to drug susceptibility
testing (DST) for S, R, H, E and Z using BACTECTM 460 or
MGIT 960. For quality assurance of DST, 245 specimens were
also tested at the CDC with over 95% concordance. The
radiometric BACTECTM 460 was used through July 2006 when
it was replaced by the fluorometric MGITTM 960. During follow-
up, two sputum samples were collected for AFB smear microscopy
and culture at each of five pre-defined time points (months 1, 2, 5,
8 and 12); additional samples were collected at later visits if
patients had a productive cough.
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Table 1. Baseline Characteristics of 96 Hospitalized New TB Patients by HIV status in Kampala, Uganda.
Factor Level HIV uninfected (n=32) HIV infected (n=64)
– n (%) (unless specified) –
Age (years) Mean (SD) 32.3 (13.8) 33.1 (8.2)
Sex Female 7 (22%) 39 (61%)
Male 25 (78%) 25 (39%)
BMI (kg/m2) Mean (SD) 16.6 (3.1) 17.5 (3.5)
Karnofsky score 70+ 20 (62.5%) 36 (56%)
#60 12 (37.5%) 28 (44%)
Duration of TB symptoms (weeks) Median (IQR) 16 (8 – 24) 12 (8 – 16)
Drug resistance status at baseline Sensitive to INH and RIF 29 (91%) 60 (94%)
Resistance to INH or RIF 2 (6%) 4 (6%)
MDR 1 (3%) 0
Extent of disease on chest radiograph Normal 0 7 (11%)
Minimal 0 14 (22%)
Moderate 3 (10%) 15 (24%)
Severe 28 (90%) 27 (43%)
Cavitation Absent 4 (13%) 49 (80%)
Present 27 (87%) 12 (20%)
Miliary infiltrate Absent 30 (97%) 58 (92%)
Present 1 (3%) 5 (8%)
Sputum AFB smear microscopy grade 1+ 3 (9%) 4 (6%)
2+ 3 (9%) 14 (22%)
3+ 5 (16%) 11 (17%)
4+ 21 (66%) 35 (55%)
BACTEC days-to-positive culture $7 days 14 (44%) 32 (50%)
,7 days 18 (56%) 32 (50%)
CD4 cell count (cells/mL) Median (IQR) - 58 (18 – 106)
Symptoms (multiple responses allowed) Fever 20 (62%) 51 (80%)
Rigors 9 (28%) 7 (11%)
Night sweats 21 (66%) 46 (72%)
Cough 32 (100%) 63 (98%)
Produce sputum 32 (100%) 62 (97%)
Purulent sputum 18 (56%) 29 (45%)
Hemoptysis 5 (16%) 2 (3%)
Dyspnea 21 (66%) 52 (81%)
Chest Pain 22 (69%) 46 (72%)
Loss of appetite 21 (66%) 53 (83%)
Diarrhoea 2 (6%) 3 (5%)
Weight Loss 26 (81%) 60 (94%)
Swollen Glands 0 12 (19%)
Malaise 23 (72%) 52 (81%)
Reason for hospitalization Low Karnofsky score 15 (47%) 46 (72%)
Diagnostic evaluation 8 (25%) 9 (14%)
Concurrent Illness 2 (6%) 10 (16%)
Haemoptysis 3 (9%) 0
Social support 2 (6%) 0
Drug side effects 0 0
Two reasons for admission 3 (9%) 2 (3%)
Other reasons 5 (16%) 1 (2%)
doi:10.1371/journal.pone.0090614.t001
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Treatment outcomes
Following WHO treatment outcome definitions, [28] subjects
were classified as cured if they completed treatment and had a
negative culture on solid medium at the end of treatment. Subjects
were classified as having completed treatment if they finished the full
8 months of therapy and were found to be free of TB symptoms at
their first post-treatment follow-up visit, but had no culture results
at the end of treatment. They were classified as having an unknown
outcome if they were lost to follow-up (the majority of these
subjects were treatment defaulters) and, classified as treatment failures
if they were culture positive at month 8 or, if they were culture
positive at month 5 with no culture at month 8 and we had no
confirmation that they were free of TB after the end of treatment.
At 8 months, a successful TB treatment outcome was defined as
cure or treatment completion with no evidence of remaining
disease, and unsuccessful outcome as treatment failure, death during
treatment, or unknown outcome. During follow up, subjects were
evaluated for TB recurrence and vital status was assessed at the
end of scheduled follow-up, which was 24 months after the
initiation of TB treatment, or the close of the study.
Statistical Analysis
The objectives of the statistical analyses were to describe the
treatment outcomes and mortality of HIV-uninfected and HIV-
infected subjects and to find factors associated with treatment
outcome and mortality. Factors were considered for inclusion in
statistical models as risk factors or confounders based on prior
knowledge or biological plausibility. [29] The number of potential
explanatory variables included in the analyses was restricted
because of the relatively small study size. A backward elimination
approach was used among the candidate regressors, bearing in
mind the need to restrict the number of regressors so that the
number of parameters in the final model was, at most, about 10%
of the number of either subjects with unsuccessful treatment
outcomes or subjects who died. For finding factors associated with
an unsuccessful treatment outcome (treatment failure, death
during the treatment period or an unknown outcome), multiple
logistic regression models were fitted both to all patients and
separately for HIV-infected patients. Survival analysis methods
were used to investigate factors associated with mortality. Kaplan-
Meier plots were drawn to compare mortality rates between HIV-
infected and HIV-uninfected subjects and, in the case of HIV-
infected subjects, to examine the impact of baseline CD4 count
and ART on mortality. Cox proportional hazards regression
models were fitted to find factors associated with mortality.
Separate models were fitted for HIV-uninfected and HIV-infected
subjects since the composite variable for baseline CD4 count and
ART status was not applicable for HIV-uninfected subjects. This
composite variable with five levels, namely ‘‘CD4 $ 200’’, ‘‘CD4
50 – 199 no ART’’, ‘‘CD4 50 – 199 ART’’, ‘‘CD4,50 no ART’’
and ‘‘CD4,50 ART’’, was a time varying covariate as some
subjects started ART sometime after commencing anti-tuberculo-
sis chemotherapy. The composite variable was used rather than
separate variables for baseline CD4 count and ART as no subject
with a baseline CD4 count of 200 cells/mL or above started ART.
The proportional hazards assumption was checked using graphical
methods as well as by the test of Grambsch and Therneu.[30] All
analyses were carried out using Stata release 11.2 (College Station,
TX: StataCorp LP).
Results
Study patients
We enrolled 96 hospitalized TB patients of whom 64 (66.7%)
were HIV -infected. Table 1 compares characteristics of partic-
ipants at the time of enrolment by HIV status. The mean age of
HIV-uninfected was 32.3 years, which was similar to that of HIV-
infected (33.1 years). There was a higher proportion of females
among HIV-infected than among the HIV-uninfected (61% vs.
22%). The duration of symptoms before hospitalization was
shorter among HIV-infected (median 12 weeks, IQR 8-16) than
among HIV-uninfected (median 16 weeks, IQR 8 – 24). The
prevalence of different symptoms at the time of time of admission
was similar in the 2 groups. Cavitation on chest X-ray was
observed more frequently in HIV-uninfected (87%) compared to
HIV-infected (20%) and a higher proportion of HIV-uninfected
were judged to have severe disease on the chest X-ray (90% vs.
43%). HIV-infected patients generally presented with advanced
AIDS (median CD4 cell count 58 cells/ml). Six patients (2 HIV-
uninfected and 4 HIV-infected) had mono-resistance to INH or
RIF and one patient (HIV uninfected) had primary MDR-TB.
Patients were hospitalized for a median period of 32 days (IQR
22 – 56). The most frequent reason for hospitalisation was low
Karnofsky score, with this being more common among HIV-
infected patients (72% vs. 47% for HIV-uninfected patients). The
proportion of patients admitted for diagnostic evaluation was
higher among the HIV-uninfected (25% vs. 14%). Ten (16%)
HIV-infected patients were admitted due to concurrent illness and
three HIV-uninfected patients were admitted for haemoptysis and
two for social reasons (Table 1).
Follow up and treatment adherence
The follow-up of participants over the course of their 8-month
anti-tuberculosis therapy is shown in Figure 1. During TB
treatment, 9 (9%) participants were lost to follow-up and 35
(36%) died. After completing treatment, the 52 (54%) patients
retained in the treatment cohort were followed for between 1 and
43 months (median 21 months, IQR 5 – 37). A further 17 (18%)
participants died (16 HIV-infected, one HIV uninfected) and two
Figure 1. Study profile during the 8-month TB treatment
period. Note: Of the 19 HIV uninfected who were still in the study at
month 8, 17 were classified as cured/completed, 1 failed treatment and
was put on a retreatment regimen and 1 had an unknown outcome. Of
the 33 HIV infected who were still in the study at month 8, 22 were
classified as cured or completed treatment, 7 failed treatment (of whom
5 were put on retreatment) and 4 had unknown outcomes.
doi:10.1371/journal.pone.0090614.g001
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Table 2. TB outcomes by HIV status and other factors.
Study Group Treatment Outcome – n (%) –
Cured/Completed Died before Month 8 Failed Unknown Totals
HIV-uninfected (n = 32) 17 (53%) 10 (31%) 1(3%) 4 (13%) 32
Age (years) #30 11 (55%) 5 (25%) 1 (5%) 3 (15%) 20
.30–40 2 (40%) 2 (40%) 0 1 (20%) 5
.40 4 (57%) 3 (43%) 0 0 7
Sex Female 3 (43%) 2 (29%) 1 (14%) 1 (14%) 7
Male 14 (56%) 8 (32%) 0 3 (12%) 25
Resistance status Sensitive to RH 15 (52%) 9 (31%) 1(3%) 4 (14%) 29
Resistant to R or H or both 2 (67%) 1 (33%) 0 0 3
Adherence in continuation phase * (Almost/)Fully compliant 11 (73%) 1 (7%) 1 (7%) 2 (13%) 15
Missed half or more 4 (80%) 0 0 1 (20%) 5
Duration of TB symptoms (months) ,3 months 4 (36%) 2 (18%) 1(9%) 4 (36%) 11
3–6 months 6 (43%) 8 (57%) 0 0 14
. 6 months 7 (100%) 0 0 0 7
BMI kg/m2 (grouped) #15 5 (62.5%) 2 (25%) 0 1 (12%) 8
.15–18.5 6 (50%) 3 (25%) 0 3 (25%) 12
.18.5 6 (50%) 5 (42%) 1(8%) 0 12
Extent of disease on X-ray * Normal 0 0 0 0 0
Minimal 0 0 0 0 0
Moderate 1 (33%) 1 (33%) 0 1 (33%) 3
Severe 15 (54%) 9 (32%) 1 (4%) 3 (11%) 28
Cavitation * No 1 (25%) 2 (50%) 0 1 (25%) 4
Yes 15 (56%) 8 (30%) 1 (4%) 3 (11%) 27
Days to positivity 7+ 9 (64%) 2 (14%) 1 (7%) 2 (14%) 14
,7 8 (44%) 8 (44%) 0 2 (11%) 18
HIV infected (n = 64) 22 (34%) 25 (39%) 7 (11%) 10 (16%) 64
Age (years) #30 12 (43%) 9 (32%) 3 (11%) 4 (14%) 28
.30–40 5 (19%) 13 (50%) 3 (12%) 5 (19%) 26
.40 5 (50%) 3 (30%) 1 (10%) 1 (10%) 10
Sex Female 18 (46%) 16 (41%) 2 (5%) 3 (8%) 39
Male 4 (16%) 9 (36%) 5 (20%) 7 (28%) 25
Resistance status Sensitive to RH 20 (33%) 23 (38%) 7 (12%) 10 (17%) 60
Resistant to R or H or both 2 (50%) 2 (50%) 0 0 4
Adherence in continuation phase * (Almost/)Fully compliant 16 (44%) 10 (28%) 5 (14%) 5 (14%) 36
Missed half or more 5 (42%) 4 (33%) 0 3 (25%) 12
Duration of TB symptoms (months) ,3 months 12 (30%) 16 (40%) 4 (10%) 8 (20%) 40
3–6 months 7 (35%) 9 (45%) 2 (10%) 2 (10%) 20
. 6 months 3 (75%) 0 1 (25%) 0 4
BMI kg/m2 (grouped) #15 7 (41%) 7 (41%) 2 (12%) 1 (6%) 17
15–18.5 12 (35%) 13 (38%) 4 (12%) 5 (15%) 34
.18.5+ 2 (17%) 5 (42%) 1 (8%) 4 (33%) 12
Extent of disease on X-ray * Normal 2 (29%) 3 (43%) 1 (14%) 1 (14%) 7
Minimal 4 (29%) 7 (50%) 2 (14%) 1 (7%) 14
Moderate 6 (40%) 7 (47%) 0 2 (13%) 15
Severe 10 (37%) 8 (30%) 4 (15%) 5 (19%) 27
Cavitation * No 18 (37%) 20 (41%) 7 (14%) 4 (8%) 49
Yes 2 (17%) 5 (42%) 0 5 (42%) 12
Days to positivity 7+ 10 (31%) 14 (44%) 3 (9%) 5 (16%) 32
,7 12 (38%) 11 (34%) 4 (12%) 5 (16%) 32
doi:10.1371/journal.pone.0090614.t002
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(3.4%) were lost to follow-up (one HIV-infected and one HIV
uninfected). The remaining patients either completed a total of 24
months of follow-up or were seen at a follow-up visit during the
last three months of the study. Adherence to TB treatment during
the continuation phase was similar for HIV-uninfected and HIV-
infected patients. Adherence information was missing in 12 HIV-
uninfected and 16 HIV-infected patients, mostly because the
patients had died or were lost to follow-up before adherence
information could be collected.
Tuberculosis Treatment Outcomes
TB treatment outcomes by HIV status and potential explanatory
factors are shown in Table 2. The results of fitting multiple logistic
regression models, firstly to all patients and secondly to the 64 HIV-
infected patients as a planned sub-group analysis, are shown in
Table 3. Overall 39 (41%) patients had a successful treatment
outcome (cured or completed treatment), with the proportion being
higher for the HIV uninfected (53%) than for the HIV infected
(34%). Factors associated with a favourable outcome among HIV-
uninfected patients were age (with patients aged 30–40 years being
less likely to have a favourable outcome) and sputum bacterial load
as measured byMGIT DTP, with those patients for whom the DTP
was 7 days or more being more likely to have a favourable outcome.
Among the HIV infected patients there was a similar age effect, with
those patients aged 31–40 being less likely to have a favourable
outcome and an effect of sex, with female patients being more likely
to have a favourable outcome. In the multiple logistic regression
models for an unfavourable outcome, the only factor that reached
statistical significance in the overall model was the duration of TB
symptoms (Table 3), with a longer interval being associated with
more favourabe outcomes with an adjusted Odds Ratio (aOR) of
0.93 for a one week increase in the duration of symptoms (95% c.i.
0.89 – 0.98; P= 0.002). The odds of having an unfavourable
outcome were higher for the HIV infected patients although this did
not approach statistical significance (aOR=1.70; 95% c.i. 0.68 –
4.29; P= 0.26). In the sub-analysis restricted to the HIV co-infected
patients, both age and sex were associated with a poor outcome,
with those aged 30–40 years being most likely to have an
unfavourable outcome, and males more likely than females to have
an unfavourable outcome (aOR=7.77; 95% c.i. 1.55 – 38.8;
P= 0.004).
Table 3. Results of fitting multiple logistic regression models for factors associated with unsuccessful outcomes.
(1) Overall model
Factor Level Adjusted Odds Ratio1 95% confidence limits P-value
HIV status Uninfected 1 Reference level 0.26
Infected 1.7 ( 0.68; 4.29)
Duration of TB symptoms 1 week increase 0.93 (0.89; 0.98) 0.002
(2) Model for HIV-infected patients only
Age group 18 – 30 1 Reference level 0.034
.30 – 40 2.68 0.73; 9.83
. 40 0.25 0.04; 1.69
Sex Female 1 Reference level 0.004
Male 7.77 ( 1.55; 38.8)
1Odds ratios adjusted for other terms in the model
doi:10.1371/journal.pone.0090614.t003
Figure 2. Survival of subjects by HIV status.
doi:10.1371/journal.pone.0090614.g002
Figure 3. Mortality by CD4 cell count at baseline and ART use
among HIV-infected subjects.
doi:10.1371/journal.pone.0090614.g003
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Survival
Mortality rates by HIV status and potential explanatory factors
are shown in table 4. Overall, 52 (54%) patients died of which 35
(36%) died during TB treatment and 17 (18%) died during the
post TB treatment period. The mortality rate (per 100 person
years at risk) was significantly higher for the HIV infected patients
(41 deaths, rate 46.9 per 100 pyar) than for the HIV-uninfected
patients (11 deaths, rate 19.7 per 100 pyar) (Figure 2). Among
HIV-uninfected patients, the mortality rate was higher for those
aged 30–40 years (43.0 per 100 pyar), for those with a Karnofsky
score on admission of 60 or less (72.6 per 100 pyar), those without
cavitation on chest X-ray (38.7 per 100 pyar) and for those who
had TB symptoms for 3–6 months. Among HIV-infected patients,
the rate was higher for those aged 30–40 (70.0 per 100 pyar), for
males (50.7 per 100 pyar), for those with a BMI above 18.5 kg/m2,
for those with a Karnofsky score on admission of 60 or less (94.6
per 100 pyar), for those with some anti-TB drug resistance (91.2
per 100 pyar) and for those with an AFB sputum smear grade of
3+ (72.0 per 100 pyar). Mortality rates were also significantly
higher for patients with CD4 cell counts below 200 cells/mL who
were not on ART (rate 76.5 per 100 pyar) for those with CD4
counts 50–199 (rate 194 per 100 pyar) and for those with CD4
counts below 50 (Figure 3). In the multivariable Cox regression
model for factors affecting survival among HIV-uninfected
Table 4. Mortality by HIV status and potential explanatory factors.
HIV-uninfected HIV infected
Factor Level n Deaths
Mortality rate per 100 pyo
(95% c.i.) n deaths
Mortality rate per 100 pyo
(95% c.i.)
Overall 32 11 19.7 (10.9; 35.5) 64 41 46.9 (34.6; 63.7)
Age ,30 20 5 13.2 (5.5; 31.9) 28 17 40.1 (24.9; 64.5)
(years) 30–40 5 3 43.0 (13.9; 133) 26 19 70.0 (44.7; 109)
.40 7 3 26.7 (8.6; 82.7) 10 5 28.1 (11.7; 67.4)
Sex Female 7 2 13.0 (3.2; 51.9) 39 25 44.8 (30.3; 66.3)
Male 25 9 22.2 (11.6; 42.7) 25 16 50.7 (31.1; 82.8)
BMI1 (kg/m2) #15 8 2 15.2 (3.8; 61.0) 17 10 33.9 (18.2; 63.0)
.15–18.5 12 4 19.3 (7.2; 51.4) 34 20 41.7 (26.9; 64.7)
.18.5 12 5 22.7 (9.4; 54.5) 12 10 111 (59.8; 206)
Karnofsky Score 70 + 20 2 4.6 (1.1; 18.4) 36 16 26.3 (16.1; 42.9)
# 60 12 9 72.6 (37.8; 139) 28 25 94.6 (63.9; 140)
Resistance Status Sens HR 29 10 19.6 (10.6; 36.5) 60 38 45.2 (32.9; 62.1)
Res H/R or both 3 1 20.0 (2.8; 142) 4 3 91.2 (29.4; 282)
Sputum smear grade 1+ or 2+ 6 1 10.8 (1.5; 76.3) 18 11 41.2 (22.8; 74.3)
3+ 5 1 8.0 (1.1; 56.6) 11 9 72.0 (37.5; 138)
4+ 21 9 26.4 (13.7; 50.8) 35 21 43.6 (28.5; 66.9)
Extent of disease on chest
X-ray
Norm/Min 0 0 - 21 14 64.6 (38.3; 109)
Moderate 3 1 19.4 (2.7; 138) 15 9 36.1 (18.8; 69.4)
Severe 28 10 21.2 (11.4; 39.5) 27 17 43.8 (27.2; 70.4)
Cavitation No 4 2 38.7 (9.7; 154) 49 31 43.9 (30.9; 62.4)
Yes 27 9 19.1 (10.0; 36.8) 12 8 66.7 (33.3; 133)
Duration of TB symptoms ,3 months 11 3 14.7 (4.7; 45.5) 40 27 49.9 (34.2; 72.8)
3–6 months 14 8 44.1 (22.1; 88.2) 20 12 48.7 (27.7; 85.7)
. 6 months 7 0 0 4 2 23.3 (5.8; 93.1)
DTP $7 days 14 2 5.9 (1.5; 23.6) 32 19 40.7 (26.0; 63.8)
, 7 days 18 9 40.9 (21.3; 78.6) 32 22 54.1 (35.6; 82.1)
ART & CD4 group CD4$200 8* 3 17.0 (5.5; 52.7)
CD4 50–199, no Art 18 12 76.5 (43.4; 130)
CD4 50–199, ART 7 1 4.9 (0.68; 34.5)
CD4,50, no ART 21 20 194 (120; 300)
CD4,50. ART 8 3 15.1 (4.9; 46.7)
Adherence Almost/fully 15 2 6.4 (1.6; 25.4) 36 23 40.0 (26.6; 60.2)
Missed half 5 0 0 12 6 29.9 (13.4; 66.6)
No Info 12 9 114 (59.2; 218) 16 12 122 (69.1; 214)
* This is a time varying covariate; numbers are those for whom the category was their final category
doi:10.1371/journal.pone.0090614.t004
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patients (table 5), the only factors associated with increased risk of
death were baseline Karnofsky score, with mortality higher for
those with a Karnofsky score of 60 or less at baseline [adjusted
Hazard Ratio (aHR) 8.93, 95% c.i. 1.88 – 42.4; P= 0.001], and
DTP which was marginally significant, with subjects with DTP,7
days having higher mortality (aHR=3.44; 95% c.i. 0.73 – 16.1;
P = 0.08). Among HIV-infected patients, the factors independently
associated with mortality were Karnofsky score, with patients with
a Karnofsky score of 60 or less having a higher mortality rate
(aHR=2.02; 95% c.i. 1.02 – 4.01; P= 0.045), and the composite
factor of CD4 count and ART, with overwhelming evidence
(P,0.001) that mortality varied with the level of this factor, with
those with CD4 counts below 200 who were not on ART at
increased risk compared to patients with a CD4 above 200
(aHR=3.59 for those with CD4 50–199 and aHR=6.90 for those
with a CD4,50) and those on ART at a reduced risk even
compared to those with a CD4 above 200 (who were not on ART
due to the prevailing treatment guidelines at the time of the study).
Discussion
In this prospective cohort study in Uganda we documented that
most new TB patients are hospitalized because of severe TB
illness, for diagnostic evaluation or concurrent illness. Unsuccessful
treatment outcome and mortality were high: 59% and 54.2%
respectively. The major determinants of mortality were severe
disease at the time of hospitalization, HIV infection and no ART
in those with CD4,200 cells/ml, especially in those with
CD4,50 cells/ml.
High mortality among TB patients in general and hospitalized
patients in particular is consistently reported in many studies [22–
24,31–34]. It is higher in resource limited settings and among
those that are HIV-infected. Some of our findings are similar to
those reported in the above studies but there are some important
differences. Firstly, the observed mortality is much higher even
when compared to other African countries. For example in
Nigeria mortality was 18% [22]. This could be attributed to the
high HIV prevalence in our cohort (over 50%). Most of these
studies were retrospective in nature while ours was prospective
with a long follow up of two years. A systematic review published
in 2011 on this subject concluded that prospective studies are
needed as most of the available studies were retrospective in nature
and relied on registries and charts [35]. This study also shows that
much of the mortality among HIV-uninfected TB patients
occurred earlier during TB treatment, while mortality in HIV-
infected patients was evenly spread through the follow up period.
Early mortality could be due to TB disease diminishing with
longer duration on TB treatment. The reduction could be due to
response to TB treatment since the prevalence of drug resistance
was low in this cohort. Persistent mortality among HIV-infected
TB patients can be explained by HIV disease progression, as
access to ART in the country was limited at the time of the study;
indeed no use of ART was found to be strongly associated with
mortality in this cohort. [36]
As regards to risk factors for death, our findings are similar to
previously reported TB mortality studies where risk factors differ
by setting [22–24,31–34]. In developed settings, non-communica-
ble diseases comorbidities, alcohol and drug abuse, and home-
lessness are the major factors; in less developed settings, the major
factors are HIV and delayed presentation for care [22–24,31–
34,37,38]. Although HIV is a major driver of mortality in TB,
mortality was also high among HIV-uninfected patients in this
study (34.5% of the HIV-uninfected cohort died). A similar result
was found in Philippines where 30% of HIV-uninfected patients
with TB died in hospital, most during the few days of
hospitalization [39]. Therefore drivers of TB mortality other than
HIV need to be addressed if TB related mortality, a key indicator
recognized by the MDG, is to be reduced [1]. Factors such as
delayed diagnosis are a reflection of poor health seeking behaviour
and inaccessible health services should be investigated and
addressed. Delayed diagnosis of TB and/or HIV has also been
previously described as a predictor of mortality among TB patients
[7,40,41]. The consistent finding of delayed diagnosis as a
predictor of mortality in previous studies highlights the need for
improved case detection and expansion of TB diagnostic and
treatment services near to the populations most at risk if TB
related mortality is to be reduced. Lack of immediate access to
effective treatment has been described as a major reason for
increased mortality in TB/HIV patients [9]. However the finding
of a reduced risk of death with increasing duration of symptoms in
the present study is rather paradoxical and needs further
investigation in larger prospective cohort studies. The poor
treatment outcomes were principally dictated by the high
mortality rates since more than one third of the patients (36%)
died during the period of hospitalization. There were however,
low rates of drug-resistance and this was not a significant
contributor to the mortality in this cohort.
Results from this study indicate that failure to start ART earlier
on during TB treatment is associated with increased mortality
among patients with CD4,200 cells/mL; mortality rates were
highest among patients with CD4,50 cells/mL who are not on
ART. This finding is similar to that from recently concluded
clinical trials in which delayed ART was associated with much
higher mortality among patients with CD4,50 cells/mL [42–44].
For patients with advanced immune suppression the possibility of
initiating ART during hospitalization for TB treatment should be
considered although the possibility of drug toxicity and immune
reconstitution should be weighed against the benefits of treatment
as these have been reported in studies investigating TB/HIV co-
treatment[43,45].
This study had some limitations. The study participants were a
highly selected population, as most newly diagnosed TB patients
are not admitted to hospital, and the findings cannot therefore be
extrapolated to other TB patients in ambulatory settings. Also the
Table 5. Mortality – results of fitting Cox proportional
hazards regression models by HIV status.
Factor Level
Hazard Ratio (95%
c.i.) P-value
(1) HIV-uninfected subjects (n = 32)
Karnofsky score 70+ 1 0.001
# 60 8.93 (1.88; 42.4)
DTP $ 7 1 0.08
, 7 days 3.44 (0.73; 16.1)
(2) HIV-infected subjects (n = 64)
Baseline CD4 & ART CD4 $ 200 cells/mm3 1 ,0.001
CD4 50–199, no ART 3.59 (0.97; 13.2)
CD4 50–199, ART 0.28 (0.029; 2.73)
CD4,50, no ART 6.90 (1.89; 25.2)
CD4,50, ART 0.77 (0.15; 3.85)
Karnofsky Score 70 + 1 0.045
# 60 2.02 (1.02; 4.01)
doi:10.1371/journal.pone.0090614.t005
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study size was small with respect to HIV-uninfected patients and
an exhaustive investigation of known predictors of poor treatment
outcomes such as hypoalbunaemia, hyponatraemia, anaemia,
neutrophilia and lymphopenia were not investigated. It must also
be noted that the study started before the availability of ART in
the public sector in Uganda and that under current guidelines all
HIV co-infected patients would receive ART especially so if their
CD4 cell counts are below 200 cells/mL.
In conclusion, this study has demonstrated that poor health
status is a major cause of hospitalisation for new TB patients. Once
hospitalised, these patients have a high frequency of poor
treatment outcome and mortality that appears to be driven by
severity of illness, HIV/AIDS and no use of antiretroviral therapy
if CD4 cell count is below 200 cells/ml. Early case detection and
effective treatment for both tuberculosis and HIV would probably
lead to reduction of hospitalization and reduce TB related
mortality.
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